Abstract
The attempts to increase novel drug productivity through creative discovery technologies have fallen short of producing the satisfactory results. For these reasons, evolved from the concept of drug repositioning, “privileged structure”-guided scaffold re-evolution/refining is a primary strategy to identify structurally novel chemotypes by modifying the central core structure and the side-chain of the existing active compounds, or to exploit undescribed bioactivites by making full use of readily derivatized motifs with well-established synthetic protocols. Herein, we review the basic tricks of exploiting privileged structures for scaffold re-evolution/refining. The power of this strategy is exemplified in the discovery of other new therapeutic applications by refining privileged structures in anti-viral agents.
Keywords: Drug design, drug repositioning, privileged structure, scaffold re-evolution, scaffold refining.
Combinatorial Chemistry & High Throughput Screening
Title:"Old Friends in New Guise": Exploiting Privileged Structures for Scaffold Re-Evolution/Refining
Volume: 17 Issue: 6
Author(s): Yu'ning Song, Wenmin Chen, Dongwei Kang, Qingzhu Zhang, Peng Zhan and Xinyong Liu
Affiliation:
Keywords: Drug design, drug repositioning, privileged structure, scaffold re-evolution, scaffold refining.
Abstract: The attempts to increase novel drug productivity through creative discovery technologies have fallen short of producing the satisfactory results. For these reasons, evolved from the concept of drug repositioning, “privileged structure”-guided scaffold re-evolution/refining is a primary strategy to identify structurally novel chemotypes by modifying the central core structure and the side-chain of the existing active compounds, or to exploit undescribed bioactivites by making full use of readily derivatized motifs with well-established synthetic protocols. Herein, we review the basic tricks of exploiting privileged structures for scaffold re-evolution/refining. The power of this strategy is exemplified in the discovery of other new therapeutic applications by refining privileged structures in anti-viral agents.
Export Options
About this article
Cite this article as:
Song Yu'ning, Chen Wenmin, Kang Dongwei, Zhang Qingzhu, Zhan Peng and Liu Xinyong, "Old Friends in New Guise": Exploiting Privileged Structures for Scaffold Re-Evolution/Refining, Combinatorial Chemistry & High Throughput Screening 2014; 17 (6) . https://dx.doi.org/10.2174/1386207317666140122101631
DOI https://dx.doi.org/10.2174/1386207317666140122101631 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development
Current Pharmaceutical Design Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
Current Gene Therapy Targeting DNA G-Quadruplex Structures with Peptide Nucleic Acids
Current Pharmaceutical Design The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery
Current Drug Targets Toxicogenomics to Evaluate Endocrine Disrupting Effects of Environmental Chemicals Using the Zebrafish Model
Current Genomics The Interplay between Cofilin and Phospho-Cofilin: Its Role in Maintaining Blood Brain Barrier Integrity
CNS & Neurological Disorders - Drug Targets Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety Aminobisphosphonates and Toll-Like Receptor Ligands: Recruiting Vγ9Vδ2 T Cells for the Treatment of Hematologic Malignancy
Current Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Artificial Intelligence Techniques for Colorectal Cancer Drug Metabolism: Ontologies and Complex Networks
Current Drug Metabolism The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets High-throughput Screening Identifies Small Molecule Inhibitors of Molecular Chaperones
Current Pharmaceutical Design A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Clinical Experience with Thalidomide and Lenalidomide in Multiple Myeloma
Current Cancer Drug Targets